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ABSTRACT
Copper oxide (CuO) nanoparticles (NPs) and copper carbonate nanoparticles (Cu2CO3(OH)2 NPs
have applications as antimicrobial agents and wood preservatives: an application that may lead
to oral ingestion via hand to mouth transfer. Rats were exposed by oral gavage to CuO NPs and
Cu2CO3(OH)2 NPs for five consecutive days with doses from 1 to 512mg/kg and 4 to 128mg/kg
per day, respectively, and toxicity was evaluated at days 6 and 26. Both CuO NPs and
Cu2CO3(OH)2 NPs induced changes in hematology parameters, as well as clinical chemistry
markers (e.g. increased alanine aminotransferase, ALT) indicative of liver damage For CuO NPs
histopathological alterations were observed in bone marrow, stomach and liver mainly consist-
ing of an inflammatory response, ulceration, and degeneration. Cu2CO3(OH)2 NPs induced mor-
phological alterations in the stomach, liver, intestines, spleen, thymus, kidneys, and bone
marrow. In spleen and thymus lymphoid, depletion was noted that warrants further immunotox-
icological evaluation. The NPs showed partial dissolution in artificial simulated stomach fluids,
while in intestinal conditions, the primary particles simultaneously shrank and agglomerated
into large structures. This means that both copper ions and the particulate nanoforms should
be considered as potential causal agents for the observed toxicity. For risk assessment, the low-
est bench mark dose (BMD) was similar for both NPs for the serum liver enzyme AST (an indica-
tion of liver toxicity), being 26.2mg/kg for CuO NPs and 30.8mg/kg for Cu2CO3(OH)2 NPs. This
was surprising since the histopathology evidence demonstrates more severe organ damage for
Cu2CO3(OH)2 NPs than for CuO NPs.
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Materials such as wood need to be protected
against degradation induced by fungi, bacteria and
insects in order to prolong their use duration.
Copper (Cu) is the most widely used fungicide for
treating wood in contact with the soil, with no sat-
isfactory alternative available since it is the only bio-
cide that shows significant effects against soft rot
fungi and other soil borne fungi. Cu is necessary for
in-ground timber structures (use class 4 i.e. timber
treated to make it suitable to be used in direct soil
or water contact) and is a preferred antimicrobial
wood preservative due to its minimal effect on
mammals, including humans, even though it shows
a relatively high toxicity against aquatic commun-
ities (Lebow and Foster 2005; Freeman and
McIntyre 2008). Application occurs via impregnation
techniques under high pressure and via non-pres-
sure techniques like brushing, spraying, and coat-
cutting (Lebow and Foster 2005). Solid copper car-
bonate (Cu2CO3(OH)2) needs to be micronized by
milling to generate particle sizes able to penetrate
to the centimeters depths required into the wood
during pressure treatment. The resulting size
CONTACT Wim H. De Jong wim.de.jong@rivm.nl National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands
Supplemental data for this article can be accessed here.
 2018 Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-
nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed,
or built upon in any way.
NANOTOXICOLOGY
https://doi.org/10.1080/17435390.2018.1530390
distributions of micronized copper formulations
contain a considerable fraction of nanoparticles.
Woods impregnated with micronized Cu are
reported to release no other Cu species than Cu
ions (Pantano et al. 2018). At equal Cu loading per
cubic meter of wood, the form and the rate of Cu
release are comparable with wood impregnated
with molecular Cu amine. However, micronized
Cu was slightly more stable throughout aging
which was attributed to the transformations during
the wood use (Pantano et al. 2018). In comparison
with solutions of aqueous copper amine (ACA)-
treated woods, the micronized copper-treated
woods feature a lower corrosive potential, a natural
wood color, and at least the same effectiveness of
protection against fungal decomposition (Lebow
and Foster 2005; Freeman and McIntyre 2008;
Cookson et al. 2010; Akhtari, Taghiyari, and
Kokandeh 2013; Platten et al. 2014). However, the
use of nanoparticle-containing copper formulations
has led to concerns regarding their safety in general
(Clausen 2007; Evans, Matsunaga, and Kiguchi 2008,
Kartal, Green, and Clausen 2009; Civardi et al. 2016)
and specifically by hand-to-mouth transfer during
installation or use of wooden installations (Platten
et al. 2016). To the best of our knowledge, there
are no publications available on oral toxicity of
micronized Cu2CO3(OH)2, whereas the oral toxicity
of Cu ions is extremely well known with an accept-
able drinking water standard of 1.3mg/L (ATSDR,
2013). Potential transformation between particulate
and ionic forms of copper is likely, because leaching
studies have indicated that the very acidic stomach
fluids extract Cu ions from wood treated with
micronized copper (Wang et al. 2013; Santiago-
Rodrıguez et al. 2015).
Results from in vivo studies indicate that lung
inflammation and toxicity after inhalation of CuO
NPs (identical to those used in this study) resolved
over 3weeks (Gosens et al. 2016) indicating a rapid
recovery, with very little if any Cu remaining in the
body of these animals. In a different study, systemic
organ toxicity was observed after repeated intraper-
itoneal administration of CuO NPs (Privalova et al.
2014). For Cu nanoparticles, in vivo liver and kidney
toxicity was reported in mice and rats after oral
administration (Chen et al. 2006; Lei et al. 2008;
Sarkar et al. 2011; Liao and Liu 2012).
The aim of this study was to compare the tox-
icity of CuO NPs and Cu2CO3(OH)2 NPs following
short-term repeated oral exposure and to determine




CuO–NPs were obtained as a black powder from
PlasmaChem, GmbH (Berlin, Germany). The crystal-
line material exhibited a size of 15–20 nm, a specific
surface area of 47m2/g as assessed by the
Brunauer–Emmett–Teller (BET) method and a dens-
ity of 6.3 g/cm3 according to the manufacturer’s
Figure 1. (A) TEM image of nano-sized CuO NP. (B) TEM image of Cu2CO3(OH)2 NP.
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datasheet. The particles were crystalline with a
density little below bulk (6.3 g/cm3). An extensive
characterization is presented in Pantano et al.
(2018). Cu2CO3(OH)2 NPs were obtained as an aque-
ous dispersion from BASF SE, identification number
LP 17206 (30% Cu), lot nr VM3041, best before date
05.02.2017. Figure 1(A–B) shows a representative
example of CuO nanoparticles in water (Gosens
et al. 2016) and Cu2CO3(OH)2 NPs in water.
CuO NP and Cu2CO3(OH)2 NP dispersions
Milli-Q water was used to disperse the CuO NP
powder and to dilute the Cu2CO3(OH)2 NP suspen-
sions before sonication for 16min in a waterbath
(Elmasonic S100) at room temperature. Before each
administration, the nanoparticle dispersion was
evaluated by CPS Disc CentrifugeTM (CPS
Instruments Europe, Oosterhout, The Netherlands)
to determine nanoparticle size and size distribution.
Both the CuO NP and the Cu2CO3(OH)2 NP disper-
sions remained stable for up to 24 and 72 h,
respectively. Representative results are presented in
Supplementary Figure 1.
Dissolution of CuO NP and Cu2CO3(OH)2 NP
A dynamic flow-through system (Wohlleben et al.
2017) was used to determine the dissolution rate of
both CuO NP and Cu2CO3(OH)2 NP far from equilib-
rium. The solid mass of 1mg of Cu (that is 1.25mg
of CuO powder or 3.47mg of the Cu2CO3(OH)2 sus-
pension) was weighed onto a membrane (cellulose
triacetate, Sartorius Stedim Biotech GmbH,
Goettingen, Germany: 47mm diameter, 5 kDa pore
size), topped by another identical membrane, and
enclosed in flow-through cells. Two complex buffers
with standardized composition were used to mimic
the stomach and intestine conditions at 37 ± 0.5 C
(Marques, Loebenberg, and Almukainzi 2011). For
the stomach, the buffer was pH 1.6 and consisted
of sodium taurocholate 0.08mM, lecithin 0.02lM,
pepsin 0.1mg/mL, and sodium chloride 34.2mM.
For the intestine conditions, the buffer was pH 5.8
and consisted of Fed-State Simulated Intestinal
Fluid (FeSSIF) (Jantratid et al. 2008): Sodium tauro-
cholate 10mM, lecithin 2mM, maleic acid
55.02mM, sodium hydroxide 81.65mM, sodium
chloride 125.5mM, glyceryl monocholate 5mM, and
sodium oleate 0.8mM.
The eluates were determined by inductively
coupled plasma-optical emission spectrometry (ICP-
OES, Agilent 5100, Agilent Technologies, Palo Alto,
CA). After the experiment, the remaining solids
were rinsed off the membrane by particle-free
water (Milli-Q). The resulting suspension was then
pelleted onto a TEM grid held at the bottom of a
centrifuge vial within 1 h, then dried, so that the
morphology of the remaining solids could be
inspected without interference from drying artifacts
of bile salts, which are removed by this preparation.
The remaining solids were analyzed by 200 keV
bright-field TEM (Tecnai G2-F20ST or Tecnai Osiris,
FEI Company, Hillsboro, USA).
Experimental design
Male-specific pathogen-free rats (RjHan:WI) aged
8–9weeks were obtained from Janvier Labs (Le
Genest-Saint-Isle, Saint Berthevin, France). The ani-
mals were treated via oral gavage for 5 d (days
1–5). The NPs were administered by oral gavage
using a bulb tipped gavage needle attached to a
syringe. Each treatment was administered as 0.1mL
per 20 g (1mL per 200 g). For both CuO NPs and
Cu2CO3(OH)2 NPs, each dose group consisted of
eight animals of which four were sacrificed at day 6
(1 d after the last treatment) and four were sacri-
ficed at day 26 (21 d after the last treatment). The
day 26 time point was included in order to evaluate
recovery, possible persistence of effects or progres-
sion of effects induced by the NPs. See
Supplementary Table 1 for the experimental design
of the study. This study design is inspired by the
Short-Term Inhalation Study (STIS) protocol pub-
lished by Klein et al. (2012) and used by Gosens
et al. (2016) to investigate the respiratory effects of
CuO NPs.
Assuming that the CuO NPs would be largely dis-
solved in the acid environment of the stomach a
starting dose of CuO NPs was selected based on
the literature for dissolved CuSO4. The no-observed-
adverse-effect-level (NOAEL) for CuSO4 was reported
to be 16.3mg/kg b.w. (ECHA 2008). A pilot study
was conducted with two animals with a dose of
64mg/kg b.w. (days 1–5 daily). Based on observa-
tions from the pilot study, the doses administered
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in the subsequent study were vehicle control, 1, 2,
4, 8, 16, and 32mg/kg b.w. CuO NPs. These doses
were selected to be below and above the reported
NOAEL for CuSO4 (Hebert 1993). In an additional
study, one group of animals (n¼ 4) was treated
with a high dose of 512mg/kg b.w.
For Cu2CO3(OH)2 NPs, a pilot study according to
OECD TG 425 was performed to determine the
starting dose in the 5 d oral gavage toxicity study
(OECD 2008). One animal was treated orally with a
single dose of Cu2CO3(OH)2 NP. If no toxicity was
observed, the dose was increased in the next ani-
mal until a toxic response was noted. When a single
animal showed a toxic response an additional four
animals were administered with the same dose. The
highest dose chosen for Cu2CO3(OH)2 NP was
128mg/kg b.w. Cu2CO3(OH)2 NPs were administered
via gavage in the 5 d oral study as 4, 8, 16, 32, 64,
and 128mg/kg b.w. or as vehicle control.
Histopathology
At days 6 and 26, animals were killed by exsanguin-
ation from the abdominal aorta during anesthesia
by isoflurane (3.5% in oxygen) inhalation. General
macroscopic post mortem examinations were per-
formed on all animals. At the time of necropsy, the
following tissues and organs were collected and
fixed in 4% neutral buffered formaldehyde (10% for-
malin): heart, lung, thymus, liver, spleen, kidney, tes-
tes, brain, mesenteric lymph node, adrenal glands,
pancreas, prostate, seminal vesicles, epididymis, thy-
roid gland, skeletal muscle – quadriceps, stomach,
duodenum, jejunum, ileum, Peyer’s patches, cecum,
colon, rectum, skin, popliteal lymph node, femur
with bone marrow, and peripheral nerve.
Microscopic examination of routinely prepared
hematoxylin–eosin-stained paraffin sections was
performed on heart, lungs, thymus, stomach, duo-
denum, jejunum, ileum, Peyer’s patches, cecum,
colon, rectum, liver, spleen, mesenteric lymph
nodes, kidneys, adrenal glands, brain, testis (unilat-
eral), and femur with bone marrow. Microscopy was
performed on all control groups, animals treated
with CuO NPs at 32, 64, and 512mg/kg b.w. and for
Cu2CO3(OH)2 NPs-treated animals at 64 and
128mg/kg b.w.
The animal data and macroscopic findings were
manually entered into the computer system
PathDataVR . Histopathological changes of examined
sections were described according to distribution,
severity, and morphological character. Severity
scores for histopathology were assigned as follows.
Present, alteration present, severity not scored;
Grade 1, alteration present as minimal/very few/very
small size; Grade 2, alteration present as slight/few/
small size; Grade 3, alteration present as moderate/
moderate number/moderate size; Grade 4, alter-
ation present as marked/many/large size; Grade 5,
alteration present as massive/extensive number/
extensive size; N.A.D., no abnormality detected.
Hematology
On days 6 and 26, blood was collected in EDTA-
coated tubes. Hematological parameters included
WBC count, RBC count, hemoglobin (Hb), hemato-
crit (Ht), mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCHC), and platelet (PLT)
count. All hematology parameters in the blood sam-
ples were determined in an Advia 120 Hematology
Analyzer (Siemens Health Care, Berlin, Germany)
according to the manufacturer’s instructions. In
addition, blood smears were prepared for visual
evaluation depending on the results obtained with
the hematology analyzer.
Bone marrow
Bone marrow cells were collected by flushing 4ml
impuls cytometer fluid through the left femur. The
concentration of nucleated cells was determined in
a Coulter Counter.
Clinical chemistry
After collection of blood serum and storage at
–20 C, the following parameters were determined:
albumin (ALB), alkaline phosphatase (ALP), alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), gamma-glutamyl transpeptidase (GGT), amyl-
ase (AMY), creatinine kinase (CK), lactate dehydro-
genase (LDH), sodium (Na), potassium (K), glucose
(GLU), urea, creatinine (CRE), cholesterol (CHOL),
and total protein (TP). All clinical chemistry parame-
ters in the serum samples were determined in an
automatic analyzer Unicel DxC 800 Synchron
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Clinical Systems (Beckman Coulter Nederland B.V.,
Woerden, The Netherlands).
Cu determination in organs
The acid mixture used for organ sample
digestion included HNO3 (trace select ultra 69%,
Sigma-Aldrich, St. Louis, MO <0.5mg/kg) and H2O2
(trace select ultra 30%, Sigma-Aldrich, St. Louis,
MO <0.05mg/kg) in a 2:1 ratio. The microwave
system ETHOS 1600 (Milestone S.r.l., Sorisole, Italy)
was used to digest the samples, following a dedi-
cated heating programme (1min 250W, 1min
0W, 5min 250W, 3min 400W, and 3min 600W).
Afterwards, the samples were allowed to cool for
30min at room temperature. The obtained solu-
tions were transferred into PTFE tubes and diluted
to 25mL with MilliQ water. For determination of
the Cu content, an aliquot of each sample was
properly diluted and analyzed by inductively
coupled plasma mass spectrometry equipped with
a single channel Universal Cell (sp-ICP-MS NexION
350XXD, Perkin Elmer, Waltham, MA). Isotope 65Cu
was selected to quantify Cu because of the lower
polyatomic interferences (e.g. 40Ar23Na) compared
with the isotope 63Cu. Moreover, to decrease
interferences Kinetic energy discrimination (KED)
was employed, using He as a collision gas.
Samples were quantified by an external calibration
method using a multi-point curve (blank and 10
points over the concentration range from 0.5mg/L
to 5000 mg/L). Yttrium at 5 mg/L was used as an
internal standard.
Potential contamination from the laboratory
was controlled by adding at least one reagent
blank during each digestion session. The limit of
detection (LOD) and the limit of quantification
(LOQ) were calculated for each sample, and set as
the average of blanks þ3 standard deviation (SD)
and as the average of blanks þ10 SD, respect-
ively. In order to verify the accuracy and repeat-
ability of the method, six aliquots of the standard
reference material (SRM) bovine liver (NIST 1577c,
National Institute of Standards and Technology,
Gaithersburg, MD) were analyzed after every 10
samples. The average Cu concentration detected
in the SRM was 277 ± 5mg/kg, which is in agree-
ment with the reference value (262 ± 2mg/kg).
Average blank values, LOD, and LOQ were calcu-
lated by considering both the reagent and the
control blanks. Detected LOD and LOQ values
were 20 ng/L and 68 ng/L, respectively. Copper
concentration in tissues and organs from rats
exposed to CuO NPs and Cu2CO3(OH)2 NPs was
expressed on a dry weight basis,
Statistical analysis
Effects of the CuO NPs and Cu2CO3(OH)2 NPs on
various parameters in the orally exposed animals
were initially compared with vehicle control ani-
mals using ANOVA for dose–response evaluation
and a one sided Student’s T-test for group differ-
ences. Further dose response analysis was per-
formed with Bench Mark Dose (BMD) evaluation
using PROAST (version 60.1, www.rivm.nl/proast).
Dose–response models were fitted to the data and
a benchmark response (BMR) was defined. The
90%-confidence interval was derived from the fit-
ted model as previously described (De Jong et al.
2013; Gosens et al. 2015), resulting in a lower and
upper limit (BMDlow at 5% and BMDhigh at 95%,
respectively) of the associated benchmark dose.
The BMR or critical effect size (CES) for general
and specific toxicity endpoints was chosen as 5%
deviation of the control values. In this study, con-
sensus default BMR values were used as proposed
by the European Food Safety Authority
(EFSA 2009).
Results
Particle dissolution and transformation
CuO NPs and Cu2CO3(OH)2 NPs dissolve almost
completely under stomach conditions at pH1.6
within 72 h (Figure 2). During that time, the ion-
resolved dissolution rate was very similar for both
materials with 50% dissolved after about 16 h for
both materials (Figure 2). As this time is longer
than the residence time in the stomach, this sug-
gests dissolution in the stomach will be incom-
plete, and so we tested the dissolution at pH 5.8
in conditions representative of the intestine. Here
we observed that the dissolution is incomplete,
although transformation of the particles is clearly
observed via TEM (Supplementary Figure 2(f)). This
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includes a decrease in the size of the primary par-
ticles in conjunction with an increase in agglomer-
ate size resulting in larger structures. The time to
50% dissolution is 20 h for micronized copper car-
bonate (Cu2CO3(OH)2 NPs), but 50 h for CuO NPs.
Adding to this interesting difference, we observed
that dissolution occurs at much lower rates in the
simple GI-tract simulant medium with the NaNO3
buffer at pH 5.3 compared with the complex
GI-tract simulant FeSSIF-V2 (pH 5.8) (Figure 2).
Thus, the dissolution in the intestine is not only
pH driven but is likely to be accelerated by the
bile salts and other physiological substances, in
complete analogy to the interactions observed
under environmental dissolution and transform-
ation of Cu NPs (Adeleye et al. 2014; Keller et al.
2017). The effect of dissolution on nanoparticle
morphology in stomach fluid simulant and com-
plex intestinal fluid simulant is shown in
Supplementary Figure 2.
General observations
CuO NP: During the study of doses up to 32mg/kg
b.w. there were no premature deaths in the study
or overt signs of toxicity, such as reduced body or
organ weights (Supplementary Table 2(A,B)). In add-
ition, no treatment-related findings were observed
at the macroscopic observation level at autopsy.
Due to the lack of effects observed, the higher dose
of 512mg/kg b.w. was investigated. The 512mg/kg
b.w. dose induced slight weight loss in one animal
after 2 d of treatment and diarrhea after 3 d of
administration. After 4 d of administrations, two ani-
mals showed diarrhea.
Cu2CO3(OH)2 NP: Repeated oral administration of a
dose of 128mg/kg b.w. Cu2CO3(OH)2 NPs induced
severe toxic responses in the animals as indicated by
the behavior of the animals, including frequent wash-
ing and piloerection. For this reason, the animals
which had been scheduled for autopsy at day 21
after treatment were instead autopsied prematurely
at days 6 and 7. At these times, a decrease in organ
weight was observed for heart, liver, spleen, and thy-
mus whereas the adrenal glands showed an increase
in weight (Figure 3, Supplementary Table 2(C)). The
most severe decrease in organ weight was noted for
the spleen and thymus, with approximately 45% and
70% loss, respectively. For doses up to 64mg/kg b.w.
both body and organ weight determined at day 26
showed no changes compared with the vehicle-
treated animals (Supplementary Table 2(D)).
Hematology and clinical chemistry
CuO NP hematology: An overview of hematological
parameters that were affected by the 5 d oral
administration of CuO NPs nanoparticles is pre-
sented in Figure 4, whereas the extended set of
hematology parameters are presented in
Figure 2. Dissolution of Cu2CO3(OH)2 NPs (blue) and CuO NPs
(orange) during flow-through testing at 37 C. A pH1.6 stom-
ach simulant. B. pH 5.8 GI-tract simulant FeSSIF V2. C. pH 5.4
simple medium 0.1 NaNO3. Quantification of ions was by
ICP-OES.
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Supplementary Table 3(A). At day 6, the total WBC
count was slightly decreased at doses of 32 and
64mg/kg b.w., whereas a two-fold increase was pre-
sent at the dose of 512mg/kg b.w. (Figure 4). In
addition, in the animals treated with 64mg/kg b.w.
CuO NPs some red blood cell parameters (number
of red blood cells, hemoglobin content, and hem-
atocrit) were slightly decreased. For the doses
evaluated up to 32mg/kg b.w., all white and red
blood cell parameters returned to values similar to
control vehicle treated animals at day 26
(Supplementary Table 3(B)). At day 6, there was no
treatment-related effect on the cellularity of the
bone marrow (Supplementary Table 4).
CuO NP: Clinical chemistry: At day 6, alterations
in the level of alkaline phosphatase (ALP) and
Figure 3. Body and organ weight (g) in male rats after five days consecutive oral administration of Cu2CO3(OH)2 NPs. Analysis of
tissues was conducted at day 6/7 (24/48 hours after the last administration). The number of animals per group were 4 (n¼ 4).
Two groups of the dose group of 128mg/kg b.w. are presented for autopsy at days 6/7 after treatment. For one group (blocked
columns) an unscheduled autopsy was conducted due to the poor condition of the animals intended for recovery group.
Significant differences compared to vehicle treated animals. p< 0.05, p< 0.01 (ANOVA). An extended set of body weight data
are presented in Supplementary Table 2(C,D).
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Figure 4. Hematology in male rats after five days consecutive oral administration of CuO NPs. Analysis was conducted at day 6
(24 hours after the last administration). The animals treated with a dose of 512mg/kg were an extra group which were treated
subsequently and without a concurrent control. Significant differences with vehicle treated animals were determined by ANOVA
for the dose response study followed by a one sided students t-test between groups. p< 0.05, p< 0.01, p< 0.01. An
extended set of hematology parameters are presented in Supplementary Table 3(A,B).
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Figure 5. Clinical chemistry in male rats after five days consecutive oral administration of CuO NPs. The data presented represent
analysis at day 6 (24 hours after the last administration). The abbreviations represent: ALP: alkaline phosphatase; ALT: alanine ami-
notransferase; AST: aspartate aminotransferase; Fe: iron; GGT: gamma glutamyltransferase; GLU: glucose; LDH: lactate dehydrogen-
ase; SHP: plasmatic thiol groups; TBAX: total bile acids. For all groups n¼ 4 with the exception of the (pilot study) dose of 64mg/
kg in which n¼ 2. Significant differences compared to vehicle treated animals. p< 0.05 compared to vehicle control (ANOVA),p< 001 compared to vehicle control (ANOVA). Animals terated with a dose of 512mg/kg were an extra group conducted with-
out a concurrent control. An extended set of clinical chemistry parameters are presented in Supplementary Table 5(A,B).
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aspartate aminotransferase (AST) enzymes indicated
the presence of liver toxicity (Figure 5). At the dose
of 64mg/kg b.w., lactate dehydrogenase (LDH) lev-
els were also increased indicating cell and organ
damage. This was further confirmed by the high
increase for the 512mg/kg b.w. dose. All clinical
chemistry data are presented in Supplementary
Table 5(A). At day 26, only the ALP was significantly
(p< 0.05) decreased at the 2mg/kg b.w. dose group
compared with the vehicle-treated control group
(Supplementary Table 5(B)). Animals treated with
512mg/kg showed similar alterations in clinical
chemistry (low level of ALP, high level of AST, and
high level of LDH) thus supporting the data of the
dose–response study (Supplementary Table 5(A)).
There was no effect on the cellularity of the bone
marrow after treatment with CuO NPs
(Supplementary Table 4).
Cu2CO3(OH)2 NP hematology: Alterations in hema-
tological parameters after 5 d oral administration of
Cu2CO3(OH)2 NPs are presented in Figure 6,
whereas the extended set of hematology parame-
ters are presented in Supplementary Table 3(C,D).
At day 6, an increase in WBC was present for doses
of 64mg/kg b.w., which was due to an increase in
lymphocytes. At 128mg/kg b.w., the increase in
WBC was mainly due to an increase in neutrophilic
granulocytes. The decrease in the relative number
of lymphocytes can be attributed to the increase in
neutrophilic granulocytes. The absolute number of
lymphocytes was not affected by the Cu2CO3(OH)2
NPs treatment at the dose of 128mg/kg b.w. Data
for day 26 are shown in Supplementary Table 3(D).
At day 26, no alterations in hematological parame-
ters were observed compared with vehicle-treated
animals for the highest dose investigated (64mg/kg
b.w.). The dose of 128mg/kg increased RBC, HgB,
Hct, HDW, and LUC at day 6. In contrast, reticulo-
cytes were decreased on treatment with doses
above 64mg/kg, while a dose of 8mg/kg increased
reticulocytes at day 6.
There was no effect on the cellularity of the
bone marrow after treatment with Cu2CO3(OH)2 NP
(Supplementary Table 4). However, microscopic
evaluation of the bone marrow after treatment
with 128mg/kg b.w. indicated a significant shift
from erythroid cells into myeloid cells (p< 0.01,
p< 0.001), that was confirmed by histopathology
(Figure 7, Supplementary Table 4).
Cu2CO3(OH)2 NP clinical chemistry: For animals
treated with Cu2CO3(OH)2 NPs ALP was decreased
at day 6, while AST, ALT, and LDH were increased
(Figure 8). All clinical chemistry data are presented
in Supplementary Table 5(C,D). The observed
enzyme alterations in the blood indicate organ tox-
icity, including the liver. In addition, free fatty acids,
creatinine, iron, and potassium levels in blood were
increased. At day 26, only some incidental altera-
tions were observed in clinical chemistry parameters
and most parameters were back to levels similar to
control vehicle-treated animals, while those that did
show an alteration did not show a dose–response
effect (Supplementary Table 5).
Histopathology
CuO NP: In the initial dose–response study, there
were no microscopic changes observed at the high-
est dose of 64mg/kg b.w. of CuO NPs evaluated
(data not shown). The dose of 512mg/kg b.w. CuO
NPs induced histopathological alterations in the
stomach, liver, and bone marrow (Supplementary
Table 6). In the stomach, an increased incidence
and severity of submucosal glandular inflammation
with eosinophilic granulocytes was observed.
The liver exhibited slight Kupffer cell hypertrophy/
hyperplasia, inflammation composed of mixed
inflammatory cells, hepatocellular hypertrophy, hep-
atocellular necrosis, and single cell necrosis (above
the background level of minimal). Bone marrow
changes included slight increased myeloid elements
and decreased erythroid elements.
Cu2CO3(OH)2 NP: Test item-related microscopic
findings were observed in a number of organs
examined after treatment with 64 or 128mg/kg
b.w. Cu2CO3(OH)2 NPs. An overview is presented in
Supplementary Table 6. After a 5-d oral administra-
tion of Cu2CO3(OH)2 NPs, the stomach exhibited an
increased incidence and severity of submucosal
glandular inflammation with eosinophilic granulo-
cytes on day 6 (Figure 9) which was still present in
some animals after the 3-week recovery period
(Supplementary Table 6). In other parts of the GI-
tract, effects were only seen at the dose of 128mg/
kg b.w. Ulceration was observed in the cecum,
colon, and rectum (Supplementary Table 6).
Figure 10 shows ulceration of colon after 5 d treat-
ment with 128mg/kg b.w. Cu2CO3(OH)2 NPs. Other
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Figure 6. Hematology in male rats after five days consecutive oral administration of Cu2CO3(OH)2 NPs. Parameters are assessed at
day 6 (24 hours after the last administration). The number of animals per group is 4 (n¼ 4), however, for some animal blood was
not available for evaluation. An unscheduled autopsy was conducted of a 128mg/kg dose group at days 6/7 in view of the poor
condition of these animals (blocked columns, n¼ 3). Significant differences compared to vehicle treated animals. One sided stu-
dents t-test, p< 0.05, p< 0.01, p< 0.01. An extended set of hematology parameters are presented in Supplementary
Table 3(C,D).
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lesions observed in the GI-tract were apoptosis
(duodenum, ileum, and cecum) and edema (colon
and rectum).
In the liver, inflammation composed of mixed
inflammatory cells (Figure 11) occurred at day 6 in
rats treated at 64mg/kg and at 128mg/kg. These
doses also induced hepatocellular necrosis, single-
cell necrosis (Figure 11), increased mitosis, liver and
Kupffer cell hypertrophy. In the kidneys at the
128mg/kg, dose effects included tubular necrosis,
hyaline casts in the tubules, and tubular degener-
ation/regeneration (Supplementary Table 6).
For Cu2CO3(OH)2 NPs at a dose of 128mg/kg
b.w., severe lymphoid atrophy was observed in the
spleen (Figure 12) and thymus (Figure 12). In the
bone marrow, an increase in myeloid activity and a
decrease in erythroid activity were observed at
128mg/kg treatment as already indicated by
the evaluation of bone marrow cell populations
(Figure 7, Supplementary Figure 3).
In the testes, a moderate degeneration of germ
cells (including slight multinucleated giant cells)
and marked spermatid retention was observed at
the 128mg/kg dose. Also at this dose, decreased
fluid was observed in the seminal vesicles of eight
out of eight animals (Supplementary Table 6).
After the recovery period at day 26, the sub-
mucosal glandular inflammation with eosinophilic
granulocytes remained in the stomach, whereas
other histopathological alterations in the other
Figure 6. Continued.
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organs were not observed at the dose of 64mg/kg
b.w., the highest dose investigated after the recov-
ery period (Supplementary Table 6).
Organ burden
CuO NP: Rats treated with 32mg/kg b.w. exhibited
an increase in Cu content in the liver (p< 0.05) and
rats treated with 64mg/kg b.w. an increase in both
liver and the mesenteric lymph node (MLN)
(p< 0.001) (Table 1). Rats treated with 512mg/kg
b.w. showed an increase in Cu content in the liver,
lung, kidneys, spleen, thymus, and mesenteric
lymph node tissue when compared with vehicle-
treated control animals of the dose response study.
At day 26, animals treated with the 32mg/kg dose
exhibited Cu levels in all organs that were equiva-
lent to the levels in the control animals.
Cu2CO3(OH)2 NP: The Cu content of tissues after
five consecutive days of Cu2CO3(OH)2 NPs oral
administration is presented in Table 2). The lower
dose of 64mg/kg b.w. induced an increase in Cu
content in liver, kidney, testes, brain, and thymus
only. The highest dose of 128mg/kg b.w. induced
an increase in Cu content in all organs evaluated.
At day 26, the increased levels of Cu in liver, thy-
mus, and kidney for the dose of 64mg/kg b.w. had
returned to background levels whereas for the liver
and testes they were still increased (p< 0.05 and
p< 0.01, respectively), although the increase was
limited compared with day 6.
Dose–response modeling
Tables 3 and 4 show a further statistical evaluation
of the outcomes of the oral CuO NPs and
Cu2CO3(OH)2 NPs studies, using the bench mark
dose (BMD) approach with a 5% deviation of levels
in vehicle control-treated animals as the bench
mark. This analysis shows that for the liver enzyme
AST and the red blood cell parameters (RBC, Hb,
Ht), an effect could be demonstrated showing a 5%
deviation from controls both for CuO NPs and
Cu2CO3(OH)2 NPs. Histopathology confirmed the
liver toxicity at high doses. The complete BMD ana-
lysis is presented in Supplementary Tables 7 and 8
for CuO NPs and Cu2CO3(OH)2 NPs, respectively.
The lowest BMD for an effect of Cu2CO3(OH)2
NPs was the effect on the liver enzyme AST with a
dose of 30.8mg/kg directly followed by the effect
on liver weight (BMD 32.2mg/kg b.w.) (Table 4).
The accompanying BMDlow being the lower end of
the 90% confidence interval that might be used for
risk assessment was 18.8mg/kg for an AST effect
and 9.5mg/kg b.w. for the liver weight effect.
Discussion
The present study investigated the toxicity of two
Cu containing nano-formulations used for the pres-
ervation of wood products that were repeatedly
administered to rodents via oral gavage in a
repeated dose oral toxicity study.
Figure 7. Cytospin preparation of bone marrow. Abundant presence of myeloid cells in the bone marrow cell population after
being treated with 128mg/kg Cu2CO3(OH)2 NPs for five consecutive days (day 1–5). The left hand image is the vehicle control
(day 6), while the right hand image is the Cu2CO3(OH)2 NP treated animal on day 7.  Myeloid progenitor cells, # erythroid pro-
genitor cells. Magnification 500.
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Figure 8. Clinical chemistry in male rats after five days of consecutive oral administration of Cu2CO3(OH)2 NPs. Parameters were
assessed at day 6 (24 hours after the last administration). ALB: albumin; ALP: alkaline phosphatase: ALT: alanine aminotransferase;
AST: aspartate aminotransferase; BAP: biological anto-oxidant potential; Ca: calcium; Cl: chloride; ; CHOL: cholesterol; CRE: creatin-
ine; Fe: iron; GGT: gamma glutamyltransferase; GLU: glucose; K: potassium; LDH: lactate dehydrogenase; Na: sodium; ROM: reactive
oxygen metabolites; SHP: plasmatic thiol groups; TBAX: total bile acids; TBIL: total bilirubin; TG: triglycerides; TP: total protein; TTT:
total thiols. DL: detection limit. For each group of animals n¼ 4. An unscheduled autopsy was conducted for a dose group of
128mg/kg (blocked columns) at days 6/7 after treatment in view of the poor condition of the animals. p< 0.05 compared to
vehicle control (ANOVA), p<.001 compared to vehicle control (ANOVA). An extended set of clinical chemistry parameters are
presented in Supplementary Table 5(C,D).
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Investigation of the Cu2CO3(OH)2 NPs and CuO
NPs demonstrated similar dissolution characteristics
in simulated stomach conditions, while in simulated
intestine conditions, Cu2CO3(OH)2 NPs dissolved
faster. For the stomach, both CuO NPs and
Cu2CO3(OH)2 NPs exhibited approximately 50% dis-
solution at approximately 20 h during flow through
conditions, while 100% dissolution was observed
Figure 8. Continued.
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for CuSO4. Such conditions are relatively realistic for
the stomach environment; however, emptying of
the stomach in rats may be reached within 6 h
(Qualls-Creekmore, Tong, and Holmes 2010). We,
therefore, hypothesize that a fraction of both par-
ticle types would survive the fast pH-driven dissol-
ution in the stomach passage. This means NPs
would reach the intestines where they would
undergo further transformation, with the
Cu2CO3(OH)2 NPs shedding Cu ions earlier or to a
greater extent than the CuO NPs. In fact, imaging
of the particles after intestinal conditions with a pH
5.8 indicated shrinking of individual particle size
which is indicative of dissolution, but this shrinkage
was also associated with agglomeration to form
relatively large structures. These data would suggest
that it is relevant to consider the possible toxico-
logical effects of both the Cu ions and the
nanoparticles.
Cu accounts for about 80% of the CuO mass,
about 60% in Cu2CO3(OH)2, and about 40% in
CuSO4 mass. Based on these mass values and solu-
bility data, which indicates 50% dissolution, it is
possible to estimate the amount of Cu ion release
in the stomach (i.e. about 40% of mass dose for
CuO NPs, 30% of the mass dose for Cu2CO3(OH)2
Figure 9. Presence of inflammation (arrows) in the submucosa of the stomach in a rat treated with a dose of 64mg/kg b.w. of
Cu2CO3(OH)2 NP for five consecutive days. Autopsy was at day 6, 1 day after the last Cu2CO3(OH)2 NP administration. The left
image provides an overview, while the right image provides detail of inflammatory cells (arrows).
Figure 10. Presence of ulceration of colon mucosa (arrow, right image) of a rat treated with 128mg/kg b.w. of Cu2CO3(OH)2 NPs
for five consecutive days. Note severe inflammation (asterisk) and loss of colon epithelium above the area of inflammation. The
autopsy was conducted at day 6, 1 day after the last Cu2CO3(OH)2 NP administration. The left image is of the colon of a vehicle
treated control animal.
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Figure 11. Presence of toxic effects in the liver following Cu2CO3(OH)2 NP administration. The top left image represents the liver
of a vehicle control treated animal. The top right image indicates the presence of inflammation (arrow) and vacuolisation (aster-
isks) of liver parenchyma cells. The bottom image indicates single cell necrosis of liver cells (arrows). The autopsy was conducted
at day 7, 2 days after the last Cu2CO3(OH)2 NP administration. The liver with histopathological lesions was from an animal treated
with 128mg/kg b.w. of Cu2CO3(OH)2 NPs for five consecutive days (days 1-5).
Figure 12. Presence of toxic effects in the spleen following Cu2CO3(OH)2 NPs exposure. The left image shows the histology of a
normal spleen of a control animal. Note the extensive presence of lymphocytes (white pulp) (asterisks). The right image shows
lymphoid atrophy as shown by the depletion of lymphocytes (white pulp) (asterisks). The right hand image is from day 6 of an
animal treated with Cu2CO3(OH)2 NPs 128mg/kg b.w. for five consecutive days (days 1-5).
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NPs, and about 40% of mass dose for CuSO4). CuO
NPs would be hypothesized to have a higher tox-
icity than Cu2CO3(OH)2 NPs if the mechanism of
toxicity is via ion release in the stomach. However,
Cu2CO3(OH)2 NPs would have higher toxicity via
ions originating in the intestine in view of its high
dissolution in simulant intestinal fluids. To investi-
gate this further, a more sophisticated protocol
would be to use sequential buffers (Bove et al.
2017) and/or simulated full diets (DeLoid et al.
2017). Flow-through-testing (for ease of retrieving
transformed NPs, for fast time resolution on ions)
could in theory be combined with sequential buf-
fers (for added physiological realism), but that was
beyond the scope of the present investigation.
Although we tested the materials at relatively low
concentration and out of equilibrium, saturation
may have suppressed dissolution rates below the
in vivo rates. In previous studies, investigating the
release of Cu ions from wood treated with
Cu2CO3(OH)2 NPs revealed more than 80% dissol-
ution after 1 h at room temperature in a simple gly-
cine simulant with pH1.5 (Santiago-Rodrıguez et al.
2015), and only slightly longer times were sug-
gested under environmental unsaturated
conditions.(Kent and Vikesland 2016; Vencalek et al.
2016). These data are in line with our own in that it
suggests the use of Cu-containing nanomaterials as
a wood preservative would result in both human
and environmental exposure to Cu ions.
In this study, the different Cu containing nano-
materials were administered to rodents for five con-
secutive days via oral gavage, before sacrificing the
animals either on days 6 and 7 or on day 26 (after
a 3week recovery period). Investigation of the bio-
distribution of CuO NPs resulted in a detectable
increase in the Cu content of the liver for doses
below 512mg/kg b.w, while at the highest dose of
512mg/kg b.w., increased Cu levels were observed
in all evaluated organs (Tables 1 and 2). Similarly,




Organ 0 32 64 512 0 32
Liver 13 ± 0.4a 42 ± 16 75 ± 4 (2) 914 ± 541 14 ± 3 12 ± 1.5
Lung 6 ± 1 6± 1 5 (1) 70 ± 69 7 ± 0.2 6 ± 1.3
Kidney 41 ± 6 62 ± 14 64 (1) 76 ± 42 62 ± 9 (3) 52 ± 4
Spleen 6 ± 0.4 6 ± 0.3 6 ± 1 (2) 10 ± 5 6 ± 0.6 5 ± 1
Thymus 4 ± 0.3 5 ± 1 (3) 8 ± 4 (2) 10 ± 7 5 ± 1 5 ± 2
MLNb 5 ± 1 8± 2 10 ± 0.3 (2) 26 ± 11 4 ± 2 5 ± 2
Testis 11 ± 0.3 11 ± 0.1 11 ± 0.3 (2) 12 ± 1 12 ± 1 11 ± 1
Brain cortex 9 ± 0.1 9 ± 0.5 ND 10 ± 1 10 ± 3 9 ± 0.4
aValues represent the Cu content in organs (mg/g tissue) at day 6 and day 26 after oral administration for 5 consecutive days (days 1-5) with CuO NPs.
Results are presented as mean ± SD, n¼ 4 unless otherwise indicated within brackets.
bMLM: mesenteric lymph node.
ND: not done. Significant differences compared to vehicle treated animals. <0.05; <0.001 students t-test, one sided.





Organ 0 64 128a 0 64
Liver 13 ± 0.5b 451 ± 58 1399 ± 307 13 ± 1 29 ± 9
Lung 8 ± 0.4 9 ± 3 259 ± 335 (8) 7 ± 0.3 7 ± 06
Kidney 29 ± 6 55 ± 13 (3) 810 ± 369 (8) 36 ± 17 28 ± 4
Spleen 5 ± 0.2 6 ± 0.6 35 ± 26 (7) 5 ± 0.2 5 ± 0.3
Thymus 4 ± 0.5 6 ± 0.6 29 ± 20 (8) 3 ± 0.3 3 ± 0.4
MLN 6± 1 7 ± 1 48 ± 23 (8) 6 ± 3 6 ± 2
Testis 11 ± 0.3 12 ± 0.2 15 ± 0.3 (8) 11 ± 0.2 13 ± 1
Brain cortex 9 ± 0.2 10 ± 0.4 11 ± 1 (8) 9 ± 0.5 10 ± 7
aOrgan content of Cu determined after a dose of 128mg/kg b.w. Cu2CO3(OH)2 NP. Animals received Cu2CO3(OH)2 NP by oral
administration for five days and organ Cu analysis was conducted at day 6 or 7. The recovery group of animals were removed
from the study in view of their poor condition.
bValues represent the Cu content in organs (mg/g tissue) at day 6 and day 26 after oral administration for five consecutive days
(days 1–5) with Cu2CO3(OH)2 NPs. Results are presented as mean ± SD, n¼ 4 unless otherwise indicated within brackets.
cMLN: mesenteric lymph node.
Significant differences compared to vehicle treated animals. <0.05; <0.01; <0.001 students t-test, one sided.
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oral exposure to Cu2CO3(OH)2 NPs at a dose of
128mg/kg b.w. increased Cu levels in all organs
investigated (liver, lung, kidney, spleen, thymus,
mesenteric lymph node, testes, brain), whereas at a
dose of 64mg/kg b.w., Cu levels were increased in
liver, kidney, thymus, testis, and brain.
In terms of toxicity, the high dose of 512mg/kg
b.w. CuO NPs induced histopathological alterations
in the stomach, liver, and bone marrow. These alter-
ations in the liver were accompanied by an increase
of liver enzymes (ALT, AST) and WBC in the blood.
Clinical chemistry effects were also observed at
lower doses (up to 64mg/kg b.w. CuO NPs) for
which histopathological alterations were not eval-
uated. This suggests that liver toxicity as indicated
by liver enzyme levels in serum might be useful
indicators for adverse effects of nanomaterials. For
CuO NPs, no impacts were observed in terms of
lymphoid depletion in the spleen and thymus.
Lower doses of CuO NPs at doses up to 32mg/kg
b.w. had limited toxic impacts compared with the
reported toxicity of soluble Cu formulations such as
CuSO4 (NOAEL of 16.3mg/kg (Hebert 1993)). The
partial dissolution of CuO NPs in the stomach might
explain the lower toxicity.
Interestingly, Cu2CO3(OH)2 NPs were more toxic
than CuO NPs when compared on the basis of dose
in mg/kg b.w. After 5 d of repeated dosing with
128mg/kg b.w., animals showed overt signs of tox-
icity. Both hematology and clinical chemistry indi-
cated toxic effects at the 64 and 128mg/kg b.w.
doses. Similar to the high-dose CuO NPs clinical
chemistry results, the Cu2CO3(OH)2 NPs increased
levels of AST and ALT indicating liver toxicity, while
LDH increases indicated cellular damage in general.
Treatment with Cu2CO3(OH)2 NP also induced inflam-
mation in the stomach, apoptosis in the duodenum,
ileum, and cecum, as well as ulceration in the large
intestines (cecum, colon, rectum). In the liver inflam-
mation, apoptosis, and necrosis occurred, as well as
hypertrophy which is indicative of repair of the liver.
In addition, kidney degeneration/regeneration and
necrosis was observed. Unlike CuO NPs, there was a
marked lymphoid atrophy in spleen and thymus
after the 5 d oral treatment with Cu2CO3(OH)2 NP,
accompanied by an increase in myeloid activity in
the bone marrow. In the spleen, both T (periarterio-
lar lymphoid sheath, PALS) and B cell areas (follicles)
were affected at a dose of 128mg/kg b.w. Overall,
the pathology in terms of organ damage in the GI-
tract, kidney, and the lymphoid organs (spleen, thy-
mus) was more severe for Cu2CO3(OH)2 NP com-
pared with CuO NP administration.
The dose–response effects for various toxicity
indicators were further evaluated by using the
BMD approach. The benchmark used was a 5%
alteration compared with the vehicle control, as
suggested by EFSA (2009). The BMDlow is the
lower end on the 90% confidence interval of the
BMD for which effects larger than the BMD
response are unlikely to occur, and can, therefore,
Table 3. Bench mark dose calculations for toxic effects after
oral CuO NPs exposure for five consecutive days.
Parameter BMDa BMDlow BMDhigh Ratio
RBC 35.7 23.8 115.7 4.9
Hgb 32.9 24 81.5 3.4
Hct 33.2 28.8 132 4.6
AST 26.2 16.1 27 1.7
aBMD (bench mark dose) is presented in mg/kg of orally administered
CuO NPs for five consecutive days.
BMD was calculated using the PROAST program. BMDlow and BMDhigh
indicate the lower and upper end of the 90% confidence intervals. The
ratio calculated between the BMDlow and BMDhigh gives an indication
of the size range of the confidence interval and the reliability of the
data. BMD was set at 5% deviation of control vehicle treated animals.
Table 4. Bench mark dose calculations for toxic effects after
oral Cu2CO3(OH)2 NPs exposure for five consecutive days.
Day 6–7 BMDa BMDlow BMDhigh Ratio
Parameter
Body weight 92.7 43.7 153.9 3.5
Liver weight 32.2 9.5 75.5 7.9
Thymus weight 69.1 43.1 97.2 2.3
Spleen weight 89.7 50.2 99.9 2.0
AST 30.8 18.8 42.9 2.3
ALP05b 91.5 65.6 95.6 1.5
ALP10 98.4 75.2 102.8 1.4
Fe 101.5 34.9 122.7 3.5
Uric acid 90.5 36.1 93.7 2.6
SHP 95.1 77.6 100.8 1.3
RBC 108.6 70.8 112.5 1.6
Hgb 100.5 67.7 115.1 1.7
Hct 113.1 74.6 117.2 1.6
Lymph rel 94.4 65.2 97.9 1.5
Lymf Absol 99.7 45.4 106.1 2.3
LDP05 61.8 32.2 91.1 2.8
LDP10 70.3 41.2 97.9 2.4
Day 26
AST 45.8 33.6 57.0 1.7
aBMD is presented in mg/kg of orally administered Cu2CO3(OH)2 NPs for
five consecutive days.
bALP05. The Figure 5 indicates a change due to treatment compared to
control levels with more than 5%, while ALP10 represents a change of
more than 10%.
BMD was calculated using the PROAST program. BMDlow and BMDhigh
indicate the lower and upper end of the 90% confidence interval. The
ratio calculated between the BMDlow and BMDhigh gives an indication
of the size range of the confidence interval and the reliability of the
data. BMD was set at 5% deviation of control vehicle treated animals.
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be used as starting point for the risk assessment.
BMDlow values of 16.1 and 18.8mg/kg b.w. were
calculated for serum AST alteration induced by
CuO NPs and Cu2CO3(OH)2 NPs, respectively.
These values are surprisingly similar to the NOAEL
for CuSO4. For CuSO4, the Cu ion is likely the
main toxicant. As suggested above, the Cu ions
may also play an important role in the mechan-
ism of Cu nanomaterial toxicity.
Privalova et al. (2014) administered CuO NPs
(diameter 20 nm) via the intraperitoneal route into
rats. Administration was conducted three times a
week applying a total of 19 injections including a
total dose of up to approximately 10mg/kg b.w.
which resulted in the induction of kidney lesions. In
contrast to the study by Privalova et al. (2014), we
did not observe histopathological lesions in kidney
and spleen by CuO NPs, but we did note lesions in
stomach, liver, and bone marrow after 5 d repeated
oral administration of 512mg/kg b.w. In view of the
very fast dissolution of the CuO NPs used by
Privalova et al. (2014), it might be assumed that Cu
ions were responsible for the observed toxicity. In
this respect, our results on Cu2CO3(OH)2 NPs show a
more widespread organ toxicity including severe cel-
lular depletion of spleen and thymus, as well as kid-
ney lesions which might be related to the more
complete dissolution in the GI-tract and the result-
ing higher internal Cu ion dose at the organ level.
Toxicity of CuO NPs, presumably due to the
release of Cu ions, was previously demonstrated in in
vitro cellular toxicity tests for various lung-derived
cells such as A549 cells, 16-HBE cells, and BEAS-2B
cells (Cho et al. 2013; Jing et al. 2015; Strauch et al.
2017; Ude et al. 2017). CuO NPs were found to be
more toxic compared with micrometer CuO particles
(CuO-MP) and CuCl2, when comparing doses as total
mass per mL in the cell culture medium (Strauch
et al. 2017). The toxic effect was explained by a
much higher Cu content in the cell (cellular cyto-
plasm and nucleus) after exposure to the CuO NPs
compared with CuO MP and CuCl2, followed by intra-
cellular Cu ion release. Both for Ag NPs and CuO NPs,
a higher cellular content of metal (Ag and Cu) ions
was observed in A549 and BEAS-2B cells compared
with exposure to Ag and Cu ions in the form of
AgNO3 or CuCl2, respectively (Cronholm et al. 2013).
Our data identified that the immune system may
also be severely affected by the Cu ions released
from the Cu containing nanomaterials as shown by
the severe lymphoid cell depletion in spleen and
thymus. This may have consequences for the func-
tionality of the immune system as was recently
demonstrated by us for silver nanoparticles (De
Jong et al. 2013; Vandebriel et al. 2014). In view of
the potentially high migration of nanomaterials to
the spleen, the immune system may be a target for
nanomaterial toxicity and needs consideration for a
more specific toxicity evaluation (Dobrovolskaia,
Shurin, and Shvedova 2016; Dusinska et al. 2017).
In conclusion, we observed a marked difference
in the severity of the pathological lesions in various
Figure 13. Effects of Cu2CO3(OH)2 NPs on the thymus. The left image shows the histology of a normal thymus of a control animal.
Note the extensive presence of lymphocytes in the thymus cortex (asterisks) and medulla (plus). The right image is from day 6 of
an animal treated with Cu2CO3(OH)2 NPs 128mg/kg for five consecutive days (days 1–5). The histology shows lymphoid atrophy as
shown by the low number of lymphocytes present resulting in a disappearance of demarcation between cortex and medulla.
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organs (e.g. GI-tract, kidney, spleen, and thymus)
between CuO NPs and Cu2CO3(OH)2 NPs after oral
exposure comparing dose effects in our rat study.
For animals exposed to Cu2CO3(OH)2 NPs, body
weight and severe organ weight loss were
observed. In the spleen and the thymus, the severe
weight loss was accompanied by lymphoid deple-
tion that warrants further immunotoxicological
evaluation. However, for risk assessment using the
serum liver enzyme AST as an indicator of liver tox-
icity, the BMD with a 5% deviation of the vehicle
control is 26.2mg/kg for CuO NPs and 30.8mg/kg
for Cu2CO3(OH)2 NPs: these values are surprisingly
similar. These data may be useful for deriving an
acceptable daily intake for these wood preservatives
which may then be used for a risk assessment
including exposure scenarios.
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